{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.28","value":"1130"},{"groupId":"OG001","spread":"21.3","value":"2209"},{"groupId":"OG002","spread":"17.7","value":"2816"},{"groupId":"OG003","spread":"28.4","value":"3579"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"18"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants \\<2 Age (Years)","id":"OG000","title":"<2 Age (Years)"},{"description":"Participants 2 to \\<12 Age (Years)","id":"OG001","title":"2 to <12 Age (Years)"},{"description":"Participants 12 to \\<18 Age (Years)","id":"OG002","title":"12 to <18 Age (Years)"},{"description":"Participants \\>=18 Age (Years)","id":"OG003","title":">=18 Age (Years)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Included PK population, defined as patients who had received any amount of study drug and had at least one serum concentration result available at clinical data cutoff.","reportingStatus":"POSTED","timeFrame":"PRD (0 hr), 0.5 hr P-I (infusion duration=30-60 minutes) on D1 of Cy1; at any time during visit on Cy1D8 (1 Cy=21 days)","title":"Area Under the Concentration-Time Curve (AUC) of Atezolizumab","type":"PRIMARY","unitOfMeasure":"ugxday/mL"}